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ABSTRACT  1 
Background: Olive oil (OO) consumption is associated with cardiovascular disease 2 
prevention due to both its oleic acid and phenolic content. The capacity of OO phenolics to 3 
protect against low-density lipoprotein (LDL) oxidation is the basis for a health claim by the 4 
European Food Safety Authority. Proteomic biomarkers enable early, pre-symptomatic, 5 
diagnosis of disease, making them important and effective, yet understudied, tools for primary 6 
prevention. 7 
Objective: To evaluate the impact of supplementation with OO, either low or high in 8 
phenolics, on urinary proteomic biomarkers of coronary artery disease (CAD), chronic kidney 9 
disease (CKD) and diabetes.  10 
Design: Participants (n=69) were randomly allocated (stratified block randomization 11 
according to age and body mass index (BMI)  to supplementation with a daily 20mL dose of 12 
OO either low or high in phenolics (18 mg/kg vs. 286 mg/kg caffeic acid equivalents) for 6 13 
weeks. Urinary proteomic biomarkers were measured at baseline, 3 and 6 weeks, alongside 14 
blood lipids, antioxidant capacity, and glycation markers. 15 
Results: Consumption of both OOs improved the proteomic CAD score at end-point 16 
compared to baseline (mean improvement – 0.3 for low phenolic and -0.2 for high phenolic 17 
olive oils, p<0.01), but not CKD or diabetes proteomic biomarkers. There was however no 18 
difference between groups for changes in proteomic biomarker, or any secondary outcomes 19 
including plasma triacylglycerols, oxidized LDL and LDL cholesterol. 20 
Conclusions: compared to low phenolic OO, supplementation for 6 weeks with a high 21 
phenolic content OO does not lead to an improvement in cardiovascular health markers in a 22 
healthy cohort.   23 
 24 
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INTRODUCTION  28 
Olive oil (OO) is the primary source of fat in the Mediterranean diet, associated with a lower 29 
incidence of chronic diseases, particularly cardiovascular diseases (1-3). The beneficial 30 
effects of OO consumption on cardiovascular risk factors were recognized by the Food and 31 
Drug Administration and European Food Safety Authority (EFSA) and attributed to the high 32 
levels of monounsaturated fatty acids (MUFA) and phenolic compounds (2),(4-6). The EFSA 33 
claim, in particular, identified that daily consumption of 5 mg of hydroxytyrosol and 34 
derivatives (per 20g OO dose) could protect LDL particles from oxidative damage if 35 
consumed daily (Supplementary table 1) (4).  36 
Phenolic compounds are minor components present in the non-saponifiable fraction of OO 37 
(0.5 – 1.5% of the oil) along with a great variety of other components, namely hydrocarbons, 38 
carotenes, triterpenic compounds, and phytosterols. Health beneficial properties of phenolic 39 
compounds have been attributed to their free radical scavenging potential (7), anti-40 
inflammatory properties (3) and more recently a significant role of these compounds was 41 
observed in human in the down regulation of atherosclerosis-related genes (8) and up-42 
regulation of genes involved in cholesterol efflux from cells to HDL (9), showing their 43 
nutrigenomic effects.  44 
Primary outcomes such as total cholesterol, HDL-cholesterol, LDL-cholesterol or oxidized 45 
LDL have been traditionally used to study the impact of OO consumption on cardiovascular 46 
risk. These markers are not optimal for nutritional primary prevention, as improvement would 47 
typically be detected late in the disease progression. A new class of biomarkers, urinary 48 
proteomic biomarkers enable early, pre-symptomatic, detection of disease, making them a 49 
very important, effective set of tools for primary prevention (10). Proteomic biomarkers have 50 
been used to define specific diseases, such as coronary artery disease (CAD), chronic kidney 51 
disease (CKD) and diabetes (type 1 and type 2) (11,12). 52 
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A scoring of disease absence, presence and severity is provided, based on the concentration of 53 
a group (panel) of urinary peptides measured by capillary electrophoresis coupled with mass 54 
spectrometric detection (CE-MS), allowing monitoring of progression and/or effect of 55 
treatment (13, 14). Increase or decrease in the concentration of these peptides determines the 56 
scoring value of each disease biomarker.  57 
Urinary proteomic biomarkers, while offering a presymptomatic insight on disease prevention 58 
strategies, are yet to be exploited in the context of nutrition and health claims.  59 
The primary aim of this study was to evaluate the impact of a 6 weeks suplementation with 60 
olive oils (20 mL/day) with either low or high total phenolic content on highly specific 61 
urinary proteomic biomarkers of CAD, CKD and diabetes in healthy adults. As far as we are 62 
aware, this is the first study to directly report changes in presymptomatic disease status and 63 
not on proxies associated with high disease risk (e.g.: LDL, oxidized-LDL). Secondary 64 
outcomes measured included plasma lipids profile, glucose and fructosamine levels as well as 65 
total antioxidant status.  66 
 67 
SUBJECTS AND METHODS 68 
Olive oil characteristics and methods. Olive oils with low phenolic content (refined olive 69 
oil) and high phenolic content (extra virgin olive oil), both with similar fatty acid profile, 70 
were supplied by a Portuguese olive oil producer. Analysis of fatty acids, β-sitosterol, free 71 
acidity and peroxide value was carried out according to European Union regulation for olive 72 
oils (15). The phenolic fraction of the oil was extracted by liquid-liquid extraction (LLE) 73 
based on the protocol of Owen et al. (16) with modifications. Total phenolic content was 74 
assessed spectrophotometrically and phenolic composition analysis was carried out by, UPLC 75 
(diode array and fluorescence detectors) and LC-MS methodology (Online Supplementary 76 
Method 1). 77 
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 78 
Recruitment: Participants (n=78), aged 18 to 75, were recruited via poster advertisement in 79 
Glasgow, UK, between August and September 2012. They were apparently healthy adults, 80 
non-regular olive oil consumers, not pregnant or lactating, not allergic to olives or olive-81 
derived products. Other exclusion criteria included history of chronic disease of the 82 
gastrointestinal tract, taking any form of medication other than the contraceptive pill, having 83 
taken antibiotics in the 3 months prior to recruitment, being pregnant, lactating or trying to 84 
conceive. Smokers were not excluded from the study.  85 
The sample size calculation (G Power 3.1.5 software, Kiel, Germany) used a comparative 86 
case-control follow-up design with changes in CAD score (ΔCAD) as readout variable. The 87 
study was powered to detect a difference in mean ΔCAD of 0.15 in case compared to control 88 
subjects, assuming a 0.25 a.u standard deviation for ΔCAD (17) . Assuming that control 89 
subjects would show no changes in CAD score (ΔCAD=0.00) and a 10% drop-out rate 90 
(consistent with similar nutrition studies), a total of 66 volunteers would enable to detect 91 
difference between groups (power 90%, α=0.05).  92 
The study was approved by the Ethics Committee of the College of Medical, Veterinary & 93 
Life Sciences, University of Glasgow (ref 2012071, date: 31/08/2012). Protocols were 94 
according to the Declaration of Helsinki and all participants provided informed consent at 95 
recruitment. 96 
Randomization: The trial followed a randomized, controlled, double blind parallel design. A 97 
total of 78 participants were initially recruited, 9 withdrew from the study prior to 98 
randomization (Figure 1). A stratified allocation list using block randomisation within each 99 
stratum was drawn by EC (18), according to age (above or below age 40) and body mass 100 
index (above or below BMI 25) with block sizes of n=6. The allocation sequence was 101 
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concealed to the recruiters (SS, GBC), with intervention assigned over the phone by EC. All 102 
investigators in Glasgow and participants were blinded to the sample type (sample A and B). 103 
Study design: Participants were supplied with olive oil at baseline and mid-intervention 104 
visits. For 6 weeks, they consumed a daily dose of 20 mL olive oil (not heated or cooked) as a 105 
supplement (no specific time during the day, single intake, equivalent to 6 mg of 106 
hydroxytyrosol and derivatives for the high phenolic OO), in line with the EFSA and FDA 107 
recommendations. Participants kept food diaries two days prior to the baseline visit and 108 
replicated their diet two days prior to day 21 (middle of intervention) and day 42 (end of 109 
intervention). No dietary restrictions were put in place, and a simple food frequency 110 
questionnaire, based on the EPIC consortium FFQ (19) was filled by all participants at 111 
recruitment. Compliance was assessed via scrutiny of intake logs, alongside the amount of 112 
unconsumed oil returned at mid and end visits.  113 
Sample collection: Fasting venous blood was collected at baseline (before ingestion of the 114 
first OO dose), days 21 and 42 in two 12 mL tubes, using EDTA and heparin as anti-115 
coagulant. After centrifugation at 2140 ×g for 5 min at 4ºC, plasma was aliquoted and stored 116 
at -80ºC until analysis. Spot urine samples (second urine of the day) were collected at the 117 
same time points, aliquoted and frozen at -20 ºC without any further additives, as 118 
recommended (www.eurokup.org) (20).  119 
Anthropometric measurements: Weight was measured to the nearest 100g using an electric 120 
scale (Seca, UK), height to the nearest mm using a stadiometer (Tanita B.V., The 121 
Netherlands) and waist circumference using a non-elasticated tape at the smallest abdominal 122 
position between the lowest rib and the iliac crest (participant standing, after an expiration). 123 
Blood pressure was measured using a digital automatic blood pressure monitor (Omron, UK) 124 
with the participant seated after 30 minutes of rest. 125 
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Proteomic analyses by CE-MS: A 0.7 mL aliquot of urine was thawed immediately before 126 
use and diluted with 0.7 mL of 2 M urea, 10 mM NH4OH containing 0.02% SDS, as 127 
described (21). The analysis was carried out as previously described (22) and in Online 128 
Supplementary Method 2. Accuracy, precision, selectivity, sensitivity, reproducibility, and 129 
stability of the CE-MS measurements were demonstrated elsewhere (21). Of the 189 urine 130 
samples available, one (from the high phenolic OO group) was excluded as not passing the 131 
quality control criteria.  132 
Plasma biomarkers: Commercially available kits were used to determine glucose, 133 
triacylglycerols, total and HDL cholesterol (Horiba, UK) using a semi-automatic analyzer 134 
(Cobas Mira Plus, ABX Diagnostics, France). LDL cholesterol was calculated using the 135 
equation of Friedwald (23). Oxidised LDL was analysed using an ELISA assay (Promokine, 136 
UK). Ferric reducing ability of plasma (FRAP) was determined as previously reported (23, 137 
24). Total phenolic content measurements was by the Folin-Ciocalteau method (23, 25) using 138 
gallic acid (Sigma Aldrich (UK) as standard. Samples were analyzed in duplicate, with a 139 
single analyzer run for each subject. Plasma fructosamine, a marker of protein glycation, was 140 
analysed in triplicate, as previously described (26). All coefficients of variation (CV%) were 141 
below 10%. 142 
Statistical analysis: Statistical analyses were performed by SPSS 22.0 software. Normality of 143 
variables was assessed with the Kolmogorov-Smirnoff test. Non-parametric data were log 144 
transformed and values expressed as antilogarithm. Differences between treatments for each 145 
time point were evaluated by independent t-tests and between groups using repeated measure 146 
ANOVA and post-hoc testing with Bonferonni correction (statistical significance: p < 0.05).  147 
Association with the predefined proteomic biomarkers in each sample was assessed based on 148 
the concentration of peptides detected, calculated from their normalized logarithmic 149 
amplitude in the CE-MS analysis. Peptide amplitude between groups was assessed with the 150 
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Wilcoxon t-test, as previously described (27). All peptides detected in over 30% of the 151 
samples were individually investigated. Correction for multiple testing to ensure a low 152 
number of false positives was performed assessing the false discovery rate, as described by 153 
Benjamini and Hochberg (23) as previously described for proteomic datasets (27). 154 
Multivariate linear regression analysis was used to describe the effect of selected independent 155 
variables on proteomic CAD results (CAD score). The dependent continuous variable was 156 
ΔCAD score at 6 weeks, with the independent variables listed in Table 1.  157 
 158 
RESULTS  159 
Olive oils characterization 160 
The two olive oils used in the study had a similar fatty acid profile but different phenolic 161 
composition, Table 2. Total phenolic content for the low phenolic olive oil was 18 mg/kg 162 
CAE, versus 286 mg/kg CAE for the high phenolic olive oil. Hydroxytyrosol and its 163 
derivatives were quantified by LC-MS for the high phenolic olive oil and were 6 mg/20g. 164 
Individual phenolic compounds for the high phenolic olive oil were p-coumaric acid 0.1%, 165 
luteolin 0.8%, vanillin 0.9%, apigenin 1%, tyrosol 4%, hydroxytyrosol 13% and secoiridoids 166 
80%. 167 
Study Cohort  168 
From the 69 participants included and allocated, 63 completed the study (n=34 for low 169 
phenolic and n=29 for high phenolic OO) leading to a drop-out of 9% (Figure 1). No harms or 170 
unintended effects were recorded. 171 
Dietary and anthropometric measurements 172 
Baseline characteristics of the study participants showed no statistically significant 173 
differences between the groups (Table 3).  174 
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There was a mean increase (p<0.05) of approximately 5 mm Hg in systolic blood pressure at 175 
end-point for both oils.  176 
No differences were observed for waist circumference measurements at 3 (midpoint) and 6 177 
weeks (endpoint) (Table 4). There was no difference between groups in term of weight 178 
change (as kg of body mass or unit of body mass index). The weight change was lower than 179 
expected for an energy load of 6880 kcal for the intervention based on the energy provided by 180 
20 mL of oil (density 0.91kg/L, 9 kcal/g, every day for 6 weeks), which would lead to an 181 
increase in body weight of 0.9 kg over 6 weeks. 182 
Proteomic biomarkers 183 
All participants self-reported as healthy. There were no differences between groups at 184 
baseline for their proteomic CAD, CKD or diabetes scores. Sub-analysis by gender did not 185 
show a difference between groups for these biomarkers. All baseline CAD scores were below 186 
the disease threshold of -0.14 (17). Neither supplementation with low or high phenolic olive 187 
oils had a significant effect on proteomic biomarkers score for CKD or diabetes (Table 5). 188 
Supplementation with both oils led to decreases of 0.3 (low phenolic) and 0.2 (high phenolic) 189 
units in the CAD score at endpoint (p<0.005) (Table 5). Compiled patterns for urinary 190 
proteomic biomarkers were obtained from samples for each trial arm to obtain a typical 191 
“fingerprint”. The proteomic profile monitored comprises all urinary peptides some of which 192 
belong to the specific biomarkers studies. The CAD biomarker, for example, is composed of 193 
238 peptides. Comparing the overall proteomic profiles obtained pre and post 194 
supplementation, 112 peptides changed after low phenolic OO supplementation, and 133 195 
peptides for high phenolic OO trial arm. Of these, 22 belonged to the 238-peptide CAD 196 
biomarker (17), as shown in Table 6, with 11 changed after low phenolic OO 197 
supplementation, 9 after high phenolic OO supplementation and 2 changed after 198 
supplementation with either oil. The direction of change of the identified CAD peptides is 199 
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presented in Table 6. Of the 9 peptides modified in the high phenolic group, all were 200 
increased after intervention. On the contrary, low phenolic content oil intake led to mixed 201 
impact on the 11 peptides significantly modified in that group. 202 
Plasma biomarkers 203 
There was no significant difference between groups for any of the plasma biomarkers 204 
measured. A number of significant changes within groups (between baseline and mid or end-205 
points) were observed (Tables 3 and 7). At mid-point, fasted glucose increased in both low 206 
and high OO groups. HDL cholesterol and fasted glucose increased at end-point in both low 207 
and high phenolic oil groups. There was no change in either LDL, oxidized LDL, 208 
fructosamine, or plasma total phenols within either group.  209 
The linear regression model with independent variables listed in Table 1 explained 210 
approximately 48% of the variance in Δ CAD score at 6 weeks (r = 0.69, r2 = 0.48, p = 0.001). 211 
Age, phenolic content of OO (high or low), total cholesterol and LDL-cholesterol at baseline 212 
were significant predictors (p <0.05, Table 8). High phenolic OO intake improved the CAD 213 
score change at endpoint by 0.16 units, while total cholesterol levels above 5.2 mmol/L 214 
improved the CAD score change at endpoint by 0.19 units. Being older (>40 years old), or 215 
with an LDL-cholesterol level above 1.8 mmol/L reduced the CAD score improvement at 216 
endpoint by 0.26 or 0.11 respectively. 217 
218 
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DISCUSSION 219 
This work is the first to demonstrate that OO supplementation led to a marked improvement 220 
in the urinary proteomic biomarker of diseases, over a relatively short period, in a healthy 221 
population. Our results did not demonstrate an important contribution of olive oil phenolics 222 
toward reduction of the CAD score. We could not detect any difference between groups, and 223 
regression analysis only pointed at a small effect size for phenolic content of OO as a 224 
predictor of CAD score change, when baseline measurements were accounted for.  225 
The Mediterranean diet, characterized by a relative high-fat consumption (mainly from OO), 226 
has been linked to a reduced risk of cardiovascular mortality (28, 29), along with lower 227 
incidence of myocardial infarction in countries from Southern Europe (30). The UK 228 
population is not a big OO consumer and there is potential for OO, as part of the diet, to 229 
improve cardiovascular risk factors irrespective of phenolic content.  230 
In this study, the overall change in CAD score can be qualified as high for both oils, and 231 
highly significant change in such a short period of time, with major OO components, the fatty 232 
acids, the most likely contributors to the effect observed. A previous placebo-controlled 233 
intervention with Irbesartan, (angiotensin II receptor antagonist used for the treatment of 234 
hypertension) taken at 300mg per day over 2 years in hypertensive type 2 diabetes patients, 235 
using the same CAD 238 biomarker panel, led to a 0.35 point reduction in the CAD score for 236 
the drug-controlled group (17). This decrease was associated with a reduction in the 237 
progression to diabetic nephropathy, a major vascular complication in diabetes patients. The 238 
OO intervention led to a similar change in the biomarker score over a 6 week period. Our 239 
findings, while important, need moderated as improvement of the biomarker score in a self-240 
reported healthy population does not necessarily translate into progression toward a 241 
“healthier” status. We can however conclude that OO has a major impact on the CAD 242 
biomarker, warranting further investigation into its benefits in a less healthy population. It 243 
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also indicates that the CAD biomarker could become a significant tool in nutrition and health 244 
intervention studies.  245 
The Mediterranean diet and its components is extensively studied in animal models, 246 
generating hypothesis toward their mechanism of action, such as the interaction between 247 
nitrate and fatty acids as an anti-hypertensive strategy in mice (31). While model systems 248 
have a place in food and nutrition research, there is a lack of methodologies with strong 249 
translational value, allowing investigations of nutritional supplementation in health in free 250 
living individuals. Here, we position urinary proteomics as a very valuable tool to achieve 251 
this, since the methodology measures changes in the peptidome as a direct result of disease 252 
progression and/or treatment, accounting for pathophysiological changes. Eight out of the 12 253 
sequenced peptides were significantly regulated towards the “healthy scoring”, including 4 254 
collagen alpha-1(I) chain, , one alpha-2(1) chain, one alpha-2(V) chain and one alpha-2(VI) 255 
chain fragments. Collagens are the most abundant peptides sequenced so far in the CAD 256 
biomarker (66% of all peptides) (17), with atherosclerosis associated with an increased 257 
synthesis of several extracellular matrix components, including collagen types I and III, 258 
elastin, and several proteoglycans (32). Changes in the circulating levels of collagenases may 259 
mediate these changes in peptides represented in the fingerprint, as reported in coronary 260 
atherosclerosis (10, 18), and CKD (33).  261 
There was no significant difference between the low and high phenolic OO groups for any of 262 
the plasma biomarkers, and differences were seen only within groups (HDL cholesterol and 263 
fasted glucose at end point for both groups). An increased HDL cholesterol was not detected 264 
in the high phenolic content oil group compared to low phenolic content oil group, contrary to 265 
the Eurolive study, where a direct relationship between plasma HDL cholesterol and phenolic 266 
content of the OO administered was observed (34). Nor did we observe a difference between 267 
groups for oxidized LDL levels, again contrasting with the findings for the Eurolive study, 268 
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where a linear decrease was observed with the increasing OO phenolic content (34). The 269 
reasons for these differences may be threefold and include power, design and choice of target 270 
population. Our study was not powered to detect differences between (or within) groups for 271 
plasma biomarkers such as oxidized LDL. With an effect size of 0.17 for changes in oxidized 272 
LDL between the low and high phenolic olive oil groups in the Eurolive study, a total sample 273 
of 858 participants for a parallel design (80% power, one tail) would be required.  274 
An alternative study design could have involved fat replacement, principally to avoid weight 275 
gain. However, we adopted a supplementation design to avoid the metabolic changes 276 
potentially associated with decreased consumption of other fat types. The daily intake of 20 277 
mL per day olive oil should have led to an extra 6880 kcal ingested over the duration of the 278 
study, equivalent to a projected 0.9 kg weight gain. OO consumption is associated with 279 
satiation effects (3), which may explain the lower weight gain observed in this study. The lack 280 
of significant weight gain in the high phenolic content oil group may be related to the 281 
organoleptic characteristics of the high phenolic content OO. Participants fed-back about the 282 
bitter / spicy taste of this OO, due to its phenolic content (35) (the low phenolic OO was 283 
characterized as sweet tasting). The taste might have led to lower compliance (not observed 284 
via scrutiny of intake logs and returned oil volumes), but also to a decrease in other foods 285 
consumed by this group (satiation, reduced desire to eat following intake of the bitter / spicy 286 
oil). 287 
Our design was a randomised controlled intervention of supplementation, while the Eurolive 288 
study had a cross-over design in men only, with inherent reduced variability, and OO as fat 289 
replacement. In our multiple regression modeling, gender did not predict CAD score change. 290 
Sub-analysis of our results by gender did not highlight different outcomes for the trial. Our 291 
parallel design, which included a broad range of participants in term of ages and body 292 
composition with a low dropout rate (< 10%), may offer better translational value, since it 293 
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takes in account the variability in the population, an important consideration for evidenced-294 
based guideline preparation. Selection of a third, non-olive oil placebo would have potentially 295 
strengthened the design, however finding an acceptable fat source that could be used in a 296 
blinded manner presents additional difficulties (e. g.structure and taste). The use of general 297 
population overcomes study design limitations previously commented by the EFSA Panel (4) 298 
as most human interventions have been conducted in more homogeneous male populations 299 
(4).  300 
The regression analysis highlighted that some parameters may modulate the impact of an OO 301 
supplementation in a very low or zero OO consumer population. These were age, baseline 302 
LDL-cholesterol levels, total cholesterol levels and the phenolic content of the oil. These 303 
parameters are important to consider during implementation of future OO interventions for 304 
primary prevention of diseases in such populations.  305 
We measured antioxidant capacity and total phenolic content of plasma, and showed no 306 
impact of supplementation on these markers, consistent with the facts that 1) these 307 
measurements are recognized as non-specific markers of exposure to high polyphenol diets 308 
and 2) it is unlikely that dietary supplementation is linked to a direct antioxidant effect (36). 309 
Protein glycation is relevant to end organ damage, disease pathogenesis and aging (37) and 310 
olive phenolic compounds have been reported as potent inhibitors of the formation of 311 
advanced glycation end products (38). With glycation occurring in short-lived plasma proteins 312 
and longer-lived intracellular proteins such as haemoglobin, a 6 weeks (42 days) intervention 313 
should have been long enough to detect changes in fructosamine levels (39). Neither low nor 314 
high phenolic OO had a significant impact on plasma fructosamine levels, indicative of the 315 
null/minimal contribution of the supplemented oil phenolics on pathways relevant to protein 316 
glycation, including radical scavenging or steric inhibition of protein glycation (40). This may 317 
be a matter of quantity as much as quality, as phenolics are known to exert differential 318 
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antioxidant and antiglycative activities depending on structure (1),(38, 41)-(42). Further 319 
minor variations were observed during/after supplementation with both oils: a marginal 320 
increase (~ 0.5 SD, within the normoglycaemic range) for fasted glucose levels (43), and 321 
blood pressure (approximately 5 mm Hg, within the normal blood pressure range, and normal 322 
fluctuations for systolic blood pressure, ~ 6 mmHg (44, 45)). Some of these variations can be 323 
attributable to the participants’ background lifestyle, rest and activity level.  324 
In conclusion, this study is the first to describe the significant impact of daily OO 325 
supplementation on highly-specific disease biomarkers for CAD, independent of the phenolic 326 
content of the oils. While providing additional evidence of the beneficial impact of OO, a key 327 
ingredient of the Mediterranean diet, on cardiovascular health, it especially offers new 328 
perspectives on olive oil applications. The results, obtained in a broad population group using 329 
a parallel design, are highly translatable for guidelines preparation, nutritional 330 
recommendations and will be useful to inform the implementation of large primary prevention 331 
programs in population groups where OO is not a staple.  332 
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TABLE 1 Potential Confounding Variables (n = 11) for Δ CAD score at 6 weeks used in multiple regression 
analyses 
Explanatory 
variables 
Individual factors Definition of term 
Participant Age, gender Age categorized as: < 40 or ≥ 40 years. 
characteristics   
Anthropometric BMI, waist BMI (kg/m
2) categorized as < 25 or ≥ 25; Waist circumference 
measurements circumference (cm) categorized as: ≤ 102 or > 102 for men, ≤ 88 or > 88 for 
  women. 
Blood pressure Systolic and diastolic blood Systolic blood pressure (mm Hg) categorized as: normal (90- 
 pressure 119), prehypertension (120-139), stage 1 hypertension (140- 
  159), stage 2 hypertension (160-179); Diastolic blood pressure 
  (mm Hg) categorized as: normal (60-79), prehypertension (80- 
  89), stage 1 hypertension (90-99), stage 2 hypertension (100- 
  109). 
Olive oil type Olive oil consumed Categorized as low or high phenolic olive oil. 
 during the study  
Clinical plasma Total cholesterol, Total cholesterol (mmol/L) categorized as: normal (< 5.2), 
biomarkers HDL-cholesterol, borderline ( 5.2-6.2) or high ( > 6.2); HDL-cholesterol  
 LDL-cholesterol (mmol/L) categorized as: low (< 1.0, men or < 1.3, women), 
 Oxidized-LDL medium (1.0-1.3, men or 1.3-1.5, women); ideal (≥ 1.6);     
 Triacylglycerols LDL-cholesterol (mmol/L): ideal at high risk of heart disease 
  (< 1.8), ideal at risk of heart disease (< 2.6), ideal for no risk 
  of heart disease (2.6-3.3), borderline high (3.4-4.1), high (4.1- 
  4.9), very high (> 4.9).Oxidized-LDL categorized as ≤ 287 or > 
  287 μg/L; Triacylglycerols (mmol/L) categorized as normal (< 
  1.7), borderline high (1.7-2.2), high (2.3-5.6), very high (> 5.6). 
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TABLE 2 Characteristics of the studied olive oils 
 Low phenolic 
olive oil 
High phenolic 
olive oil 
Free acidity (% oleic acid)
1
 0.03 0.35 
Peroxide value (mEq O2/kg) 0.30 7.5 
Fatty acids (%)
1
   
C14:0 0.02 0.01 
C16:0 12.1 11.7 
C16:1 1.1 0.7 
C17:0 0.1 0.1 
C17:1 0.2 0.2 
C18:0 3.0 2.7 
C18:1 73.2 73.5 
C18:2 8.7 8.6 
C18:3 0.7 0.8 
C20:0 0.4 0.4 
C20:1 0.3 0.3 
C22:0 0.1 0.1 
C24:0 0.1 0.0 
β-sitosterol (mg/kg) 1149 1262 
α-tocopherol (mg/kg) 160 234 
Total polyphenols (mg/kg CAE) 18 286 
Total polyphenols (mg/kg GAE) 21 338 
Hydroxytyrosol and derivatives 
(mg/20 g) 
0.1 6.4 
1
percentage by mass. 
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TABLE 3 Baseline characteristics of participants in the study  
 Low phenolic olive oil (n = 
34) 
High phenolic olive oil (n = 
29) 
Gender (Male/Female) (n/n) 15/19 12/17 
Ethnicity (n/n) 32 Caucasian / 2 Asian 26 Caucasian / 1 Asian / 2 
Mixed 
Age, years 30.2 ± 12.1 31.5 ± 11.9 
Weight, kg 73.7 ± 20.0 72.0 ± 15.7 
BMI, kg/m
2 
 23.9 ± 1.2
1
 24.2 ± 4.8 
Waist circumference, cm 81.7 ± 14.2 80.5 ± 13.0 
Systolic pressure, mmHg 121.5 ± 15.9 122.5 ± 12.2 
Diastolic pressure, mmHg 
 
73.2 ± 7.4 76.2 ± 8.6 
Glucose (mmol/L) 4.5 ± 1.2 4.5 ± 1.2 
Triacylglycerol ( mmol/L)
1
 0.8 ± 1.6 0.8 ± 1.6 
Total cholesterol  (mmol/L) 4.6 ± 1.5 4.3 ± 1.5 
HDL (mmol/L) 1.4 ± 0.5 1.5 ± 0.4 
LDL (mmol/L) 2.7 ± 1.1 2.4 ± 1.2 
Total Cholesterol-HDL cholesterol ratio 3.3±1.0 3.0 ± 1.0 
Oxidized LDL (μg/L)1 128.1 ± 2.4 108.8 ± 2.8 
Oxidized LDL/LDL ratio (μg/mg)1 0.1 ± 2.8 0.1 ± 3.3 
Plasma Fructosamine (μM, DMF) 284.9 ± 38.7 293.2 ± 39.9 
Plasma FRAP (Fe
2+
 mM) 0.4 ± 0.1 0.3 ± 0.1 
Plasma Total phenolic content (μg/mL, GAE) 
 
377.7 ± 50.1 374.4 ± 64.8 
Habitual fruit & vegetable intake (servings / week) 24.9 ±16.0 21.8 ± 14.6 
Habitual tea and coffee intake (servings / week) 18.5 ± 14.5 17.8 ± 14.6 
Habitual fruit juice intake (servings / week) 6.6 ± 6.6 4.8 ± 4.5 
   
Data are expressed as mean ± SD. 
1
For non-normally distributed data antilog are presented as mean ± SD. There 
were no significant differences between groups. BMI = Body mass index. HDL = high-density lipoprotein; LDL = 
low-density lipoprotein.  
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TABLE 4 Changes in anthropometric measurements (weight, BMI and waist circumference) and blood pressure at 3 and 6 weeks after intervention  
   
Low phenolic olive oil (n = 34) High phenolic olive oil (n = 29) 
  Post 
intervention 
Changes relative to 
Baseline 
Post 
intervention 
Changes relative to 
baseline 
 Weight (kg) 3 weeks 73.9 ± 19.7 0.2 ± 1.1 (-0.2 to 0.6) 71.9 ± 15.8 - 0.1 ± 2.1 (-0.9 to 0.7) 
 
 6 weeks 74.1 ± 19.7 0.4 ± 1.2 (0.1 to 0.9)  72.3 ± 15.9 0.3 ± 2.0 (-0.5 to 1.1) 
 
BMI, kg/m
2
 3 weeks 24.5  ± 5.1 0.1 ± 0.5 (-0.1 to 0.3)  24.3 ± 4.8 0.0 ± 0.7 (-0.3 to 0.3) 
  6 weeks 24.6 ± 5.1 0.2 ± 0.5 (0.0 to 0.4)  24.4 ± 4.8 0.1 ± 0.7 (-0.1 to 0.4) 
 Waist circumference, cm 3 weeks 82.0 ± 13.9 0 3 ± 2.5 (-0.6 to 1.1) 81.0 ± 12.1 0.5 ± 3.5 (-0.9 to 1.9) 
  6 weeks 82.2 ± 14.0 0.5 ± 2.3 (-0.3 to 1.3) 80.9 ± 12.6 0.3 ± 3.3 (-0.9 to 1.6) 
 Systolic pressure, mmHg 3 weeks 122.0 ± 14.5 0.5 ± 10.6 (-3.2 to 4.2) 127.1 ± 11.6 4.7 ± 7.8 (1.7 to 7.6)  
  6 weeks 127.4 ± 13.1 5.9 ± 12.6 (1.6 to 10.3)* 127.5 ± 13.1 5.0 ± 12.0 (0.5 to 9.6) * 
 Diastolic pressure, mmHg 3 weeks 74.9 ± 7.1 1.7 ± 6.3 (-0.5 to 3.9) 78.8 ± 9.3 2.6 ± 6.0 (0.3 to 4.9)  
  6 weeks 75.9 ± 7.9    2.7 ± 8.7 (-0.4 to 5.7) 77.4 ± 8.7 1.2 ± 8.1 (-1.8 to 4.3) 
Data are expressed as mean ± SD (95% Confidence Interval). Repeated measure ANOVA test (statistical significance: p < 0.05). *p<0.05 versus its 
corresponding baseline. There were no significant differences in changes between groups. 
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TABLE 5 Changes in CAD, CKD and diabetes proteomic biomarkers scoring at baseline, mid (3-weeks) and end-of-intervention (6 weeks). 
 Low phenolic olive oil (n = 34) High phenolic olive oil (n = 28) 
  Score Changes relative to baseline Score 
Changes relative to 
baseline 
CKD proteomic biomarker baseline -0.4 ± 0.2 - -0.4 ± 0.3 - 
 3 weeks -0.4 ± 0.2 0.0 ± 0.3 (-0.1 to 0.1) -0.4 ± 0.3 0.1 ± 0.3 (0.0 to 0.2) 
 6 weeks -0.4±0.2 0.0 ± 0.3 (0.0 to 0.1) -0.4 ± 0.2 0.0 ± 0.3 (-0.1 to 0.1) 
Diabetes proteomic biomarker baseline 1.3 ± 0.3 - 1.3 ± 0.3 - 
 3 weeks 1.3 ± 0.4 0.1 ± 0.4 (-0.1 to 0.2) 1.3 ± 0.3 -0.1 ± 0.4 (-0.2 to 0.1) 
 6 weeks 1.4 ± 0.4 0.1 ± 0.4 (0.0 to 0.2) 1.2 ± 0.3 0.0 ± 0.4 (-0.2 to 0.1) 
CAD proteomic biomarker baseline -0.5 ± 0.2 - -0.6 ± 0.4 - 
 3 weeks -0.7 ± 0.3 -0.2 ± 0.3 (-0.3 to -0.1) -0.7 ± 0.3 -0.1 ± 0.4 (-0.3 to 0.0) 
 6 weeks -0.8 ± 0.3 -0.3 ± 0.2 (-0.4 to -0.2)** -0.8 ± 0.3 -0.2 ± 0.3 (-0.4 to -0.1)* 
Data are expressed as mean ± SD (95% Confidence Interval). *p<0.005 versus its corresponding baseline. **p<0.001 versus its corresponding baseline. Repeated 
measure ANOVA test (statistical significance: p < 0.05). There were no significant differences in changes between groups. 
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TABLE 6 Peptides from the CAD biomarker
1 
altered after olive oil supplementation (changes from baseline) 
Peptide ID Mass CE 
migration 
time. 
(min) 
Peptide sequence
2
 Protein
2
 Change of direction 
3
 
according to treatment 
group 
4
  
5661 911.26 34.4   ↓ in LPOO 
11989 988.52 22.4   ↑ in HPOO 
16859 1,082.49 20.8   ↓ in LPOO 
21147 1,150.56 22.4 TDTEDPAKFK Retinol-binding protein 4 ↑ in HPOO 
22625 1,169.57 23.7   ↓ in LPOO but ↑ in HPOO 
24117 1,194.55 26.7 SpGPDGKTGPpGP Collagen alpha-1(I) chain ↑ in LPOO 
31525 1,312.62 22.5   ↑ in HPOO 
33135 1,338.60 24.0   ↑ in LPOO and ↑ in HPOO 
34795 1,368.58 21.9   ↓ in LPOO 
36988 1,408.66 39.1 GPPGppGPpGPPGPPS Collagen alpha-1(I) chain ↑ in HPOO 
41514 1,467.81 24.7 DQSRVLNLGPITR Uromodulin ↑ in HPOO 
42832 1,495.68 39.4 GPpGPpGPpGPpGPPSA Collagen alpha-1(I) chain ↑ in LPOO 
43828 1,512.69 26.6 SpGSDGPKGEKGDpGP Collagen alpha-2(VI) chain ↑ in LPOO 
45445 1,539.73 40.3 GpEGPpGEPGpPGPPGP Collagen alpha-2(V) chain ↑ in HPOO 
46756 1,565.69 26.3   ↑ in LPOO 
50212 1,613.82 24.0 VGGGEQPPPAPAPRRE Xylosyltransferase 1 ↑ in LPOO 
53035 1,651.79 40.7 VGPpGPpGPpGPpGPPSAG Collagen alpha-1(I) chain ↑ in HPOO 
62387 1,844.48 34.3   ↓ in LPOO 
67382 1,936.87 34.8   ↑ in LPOO 
89083 2,352.05 26.8 KGDRGETGpAGPPGApGAPGAPGPVGP Collagen alpha-1(I) chain ↑ in LPOO 
91044 2,394.08 23.6 FFLPDEGKLQHLENELTHDI Alpha-1-antitrypsin ↑ in HPOO 
114086 2,907.35 36.0 TGEVGAVGPpGFAGEKGPSGEAGTAGPpGTpGP Collagen alpha-2(I) chain ↑ in HPOO 
1
 Composed of 238 individual peptides 
2
 Out of the 22 peptides listed, only 12 have been sequenced 
3 
The arrows indicate direction of change in urinary peptide concentration.
 
4 
LPOO: low polyphenol content olive oil; HPOO: high polyphenol content olive oil 
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TABLE 7 Changes in plasma biomarkers at 3 and 6 weeks after intervention 
 Low phenolic olive oil (n = 34)  High phenolic olive oil (n = 29) 
 Post 
intervention 
3 weeks 
Changes relative 
to baseline 
3 weeks 
Post 
intervention 
6 weeks 
Changes relative 
to baseline 
6 weeks 
Post 
intervention 
3 weeks 
Changes relative 
to baseline 
3 weeks 
Post 
intervention 
6 weeks 
Changes relative to 
baseline 
6 weeks 
Glucose  
(mmol/L) 
5.1 ± 1.2 0.5 ± 1.1 
(0.1 to 0.9)* 
5.0 ± 1.2 0.50 ± 1.3 
(0.02 to 0.97)* 
5.0 ± 1.2 0.5 ± 1.1 
(0.03 to 0.91)* 
5.0 ± 1.3 0.6 ± 1.0 
(0.2 to 1.0)* 
Triacylglycerol 
(mmol/L)
1
 
0.9 ± 1.5 1.0 ± 1.5 
(0.9 to 1.2) 
0.9 ± 1.5 1.1 ± 1.5 
(1.0 to 1.3) 
0.9 ± 1.6 1.04 ± 1.4 
(0.9 to 1.2) 
0.9 ± 1.7 1.1 ± 1.4 
(0.9 to 1.3) 
Total cholesterol  
(mmol/L) 
5.1 ± 1.8 0.5 ± 1.4 
(-0.03 to 1.0) 
4.9 ± 1.8 0.4 ± 1.6 
(-0.2 to 0.9) 
4.8 ± 1.9 0.4 ± 1.5 
(-0.2 to 1.0) 
5.0 ± 2.1 0.7 ± 1.6 
(0.01 to 1.4)  
HDL  
(mmol/L) 
1.7 ± 0.7 0.2 ± 0.5 
(0.06 to 0.4) 
1.7 ± 0.6 0.2 ± 0.4 
(0.1 to 0.4) * 
1.7 ± 0.6 0.2 ± 0.6 
(-0.1 to 0.40) 
1.7 ± 0.6 0.3 ± 0.6 
(0.04 to 0.48) * 
LDL  
(mmol/L) 
2.9 ± 1.2 0.2 ± 1.0 
(-0.1 to 0.6) 
2.8 ± 1.4 0.1 ± 1.1 
(-0.3 to 0.5) 
2.6 ± 1.4 0.2 ± 0.9 
(-0.2 to 0.6) 
2.8 ± 1.6 0.4 ± 1.0 
(-0.1 to 0.8) 
Total Cholesterol:HDL 
cholesterol ratio 
3.2 ± 0.8 -0.1 ± 0.6 
(-0.4 to 0.1) 
3.1 ± 0.9 - 0.3 ± 0.5 
(-0.4 to -0.1)  
2.9 ± 0.9 -0.1±0.5 
(-0.3 to 0.1) 
2.9 ± 1.0 - 0.1 ± 0.4 
(-0.3 to 0.1) 
Oxidized LDL 
(μg/L)1 
116.9 ± 2.2 0.9 ± 1.3 
(0.9 to 1.0) 
126.4 ± 2.3 1.0 ± 1.4 
(0.9 to 1.1) 
117.0 ± 3.1 1.0 ± 1.3 
(0.9 to 1.1) 
117.7 ± 3.0 1.0 ± 1.4 
(0.8 to 1.1) 
Oxidized LDL/LDL 
ratio (μg/mg)1 
0.1 ± 2.4 0.9 ± 1.8 
(0.7 to 1.1) 
1.3 ± 1.3 1.0 ± 1.3 
(0.9 to 1.1) 
0.1 ± 3.5 0.9 ± 1.5 
(0.8 to 1.1) 
0.1 ± 3.4 0.9 ± 1.5 
(0.7 to 1.0) 
Fructosamine  
(μM, DMF) 
272.0 ± 61.0 -14.9 ± 66.1 
(-38.7 to 9.0) 
282.4 ± 44.7 -2.4 ± 51.4 
(-20.3 to 15.5) 
282.6 ± 46.0 -6.2 ± 58.2 
(-30.2 to 17.9) 
301.9 ± 41.8 8.5 ± 52.6 
(-14.3 to 31.2) 
FRAP  
(Fe2+ mM) 
0.4 ± 0.1 -0.05 ± 0.09 
(-0.08 to -0.01)* 
0.4 ± 0.1 0.03 ± 0.11 
(-0.01 to 0.06) 
0.3 ± 0.1 -0.02 ± 0.11 
(-0.07 to 0.03) 
0.4 ± 0.1 0.03 ± 0.07 
(-0.0 to 0.1) 
Total phenolic content 
(μg/mL, GAE) 
390.2 ± 60.7 9.9 ± 74.4 
(-16.9 to 36.7) 
394.2 ± 52.0 16.5 ± 74.6 
(-9.5 to 42.6) 
356.0 ± 71.8 -17.4 ± 91.5 
(-55.1 to 20.4) 
364.2 ± 79.6 -2.4 ± 100.7 
(-45.9 to 41.2) 
Data are expressed as mean ± SD (95% Confidence Interval).1 For non-normally distributed data antilog are presented as mean ± SD. *p<0.05 versus its corresponding baseline. Repeated measure 
ANOVA test (statistical significance: p < 0.05). There were no significant differences in changes between groups. 
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TABLE 8 Multiple regression analysis summary for participants’ characteristics, anthropometric measurements and clinical plasma biomarkers with Δ CAD 
score levels at 6 weeks  
Δ CAD score 6 weeks Correlation 
coefficient (r) 
Determination 
coefficient 
(r
2
 ) 
ANOVA 
significance 
(p) 
 
Model 0.690 0.476 0.001  
     
 Unstandardized  
Coefficient (B) 
Standard error Standardized  
Coefficient (β) 
p-value 
Age -0.258 0.093 -0.387 0.008 
Gender 0.081 0.068 0.142 0.237 
Olive oil type 0.164 0.069 0.289 0.022 
Systolic blood pressure 0.067 0.061 0.171 0.274 
Diastolic blood pressure -0.114 0.086 -0.200 0.194 
BMI -0.075 0.095 -0.120 0.434 
Waist circumference -0.109 0.131 -0.138 0.410 
Total cholesterol 0.193 0.086 0.472 0.029 
HDL-cholesterol 0.013 0.048 0.033 0.789 
LDL-cholesterol -0.112 0.044 -0.537 0.014 
Oxidized LDL 0.105 0.085 0.140 0.222 
Triacylglycerols 0.150 0.127 0.186 0.245 
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FIGURE 1 – Study flow diagram  
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Supplementary Method 1  
 
Liquid-liquid extraction (LLE), based on the protocol of Owen et al. (1) with modifications, 
for total phenolic content, individual phenolic compounds percentage and hydroxytyrosol 
and derivatives determination  
 
Methanol p.a. (Fischer, UK) (3 mL) was added to 2 g of olive oil and homogenized for 5 min 
with a vortex. After that, two phases were obtained by centrifugation at 3214 ×g for 30 min and 
the alcoholic phase was separated. This step was repeated twice and the extracts were combined. 
Then, the alcoholic extracts were evaporated to dryness at 35 ºC and dissolved in 2 ml 
methanol:water (80:20, v/v) using water Milli-Q quality (18.2 MΩ.cm, Millipore Corp, Bedford, 
MA, USA). 
Total phenolic content was determined in triplicate, assessed using methodology based on 
previous work (2) and expressed as caffeic acid (CAE) and gallic acid (GAE) equivalents. 
Briefly, 3.5 mL of caffeic or gallic acid (Sigma, USA) standard solutions (1-6 mg/L) or diluted 
sample was mixed with 0.1 mL of Folin–Ciocalteu reagent (Fluka, Switzerland). The solution 
was kept for 3 min without agitation. Sodium carbonate (Panreac, Spain) 35% was added to the 
solution. After 60 min of incubation at room temperature, the absorbance was read against a 
reagent blank at 750 nm on a Beckmann DU-70 (USA) spectrophotometer, with 1cm glass 
cuvette. Phenolic composition of samples was determined analyzing the LLE extract by UPLC 
after filtering using PVDF 0.22 µm filters. Standard phenolic compounds were used to obtain 
calibration curves to quantify the compounds in the olive oils. Apigenin, luteolin, hydroxytyrosol 
and  tyrosol were purchased from Extrasynthese (Genay, France). Vanillin was purchased from 
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Fluka (Switzerland) and caffeic acid, p-coumaric acid and vanillic acid were purchased from 
Sigma (USA). Standard stock solutions of each compound were prepared in methanol and 
dilutions in methanol:water (80:20, v/v). The UPLC system consisted of an AcQuity UPLC® 
Class H equipped with a quaternary pump system Waters (Milford, MA, USA) coupled to PDA 
and fluorescence detectors AcQuity UPLC® Class H. For phenolic compounds analysis an 
AcQuity UPLC® BEH Shield RP18 column (1.7 μm, 150 mm × 2.1 mm i.d.) with a VanGuard 
pre-column AcQuity UPLC® BEH C18 (2.1 mm×5 mm, 1.7 μm) also from Waters was used. 
During the analysis, the column was kept at 35 ºC and the flow-rate was 0.4 mL/min. The mobile 
phase was composed by MilliQ water and acetic acid Panreac (Spain): eluent A, water/acetic 
acid (100/0.01, v/v) and eluent B, acetonitrile (Carlo Erba, Italy). The elution started at 10% of 
eluent B, then was linearly increased to 34% of eluent B in 10min, kept isocratic for 2.0 min, 
further increased to 90% of eluent B in 6 min and then to 100% B in 0.5 min and kept isocratic 
for 6.5 min. The injection volume was 2.5 μL. For α-tocopherol determination by UPLC, 
samples were weighed (5.00 ± 0.01 g) and dissolved in 10 mL hexane (Carlo Erba, Italy) 0.1% 
BHT (Sigma, USA). A dilution (factor of 2.5) was then prepared with 2-propanol (Carlo Erba, 
Italy). The final solution was filtered through 0.22 µm filters, before UPLC analysis with 
fluorescence detection. The α-tocopherol (Sigma, USA) content was determined in duplicate 
against a standard calibration curve prepared in 2-propanol (10-90 mg/L). The chromatographic 
column used was an AcQuity UPLC® BEH Shield RP18 column (1.7 μm, 50 mm × 2.1 mm i.d.) 
equipped with a VanGuard pre-Column AcQuity UPLC® BEH C18 (2.1 mm×5 mm, 1.7 μm) 
also from Waters. During the analysis, the column was kept at 35 ºC and the flow-rate was 0.8 
ml/min. The mobile phase was a mixture of acetonitrile, 2-propanol and water (85:7.5:7.5, v/v) 
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and it was run isocratic for 4 minutes with an injection volume of 2.5 μL. The fluorescence 
detector was set to λexc 296 nm/ λem 330 nm.  
For hydroxytyrosol and derivatives assessment in olive oils HPLC-PDA-Exact Mass-MS 
analysis was carried out on a Thermo Accela HPLC system comprising an autosampler with a 
sampler cooler maintained at 15 °C, a photodiode array detector scanning from 200 to 600 nm. 
Samples (5 μL) were injected onto a 150 × 4.6 mm C18 Kinetex column (Phenomenex) 
maintained at 40 °C and eluted with a 5 −90% gradient of 0.01% acetic acid and acetonitrile at 
250 μL/min over 25 min. The eluant was directed to the electrospray interface of an Exactive 
Orbitrap mass spectrometer (Thermo Fisher Scientific). Samples were run in negative ionization 
mode, and the scan range was from 130 to 2000 amu with resolution set to 50,000. 
Quantification of hydroxytyrosol derivatives was by exact mass measurements, using 
hydroxytyrosol and tyrosol as standards, and expressed as hydroxytyrosol and tyrosol 
equivalents.  
 
 
38 
 
38 
 
Supplementary Method 2 
Urinary proteomic analysis 
 
To remove higher molecular mass proteins, such as albumin and immunoglobulin G, the sample 
was filtered using Centrisart centrifugation filter devices (20 kDa MW), supplied by Sartorius 
Stedim Limited (U.K.) at 2000 ×g until 1.1 mL of filtrate was obtained. This filtrate was then 
applied onto a disposable PD-10 desalting column supplied by GE Healthcare Biosciences AB 
(Bedford, USA) equilibrated in 0.01% NH4OH (Sigma Aldrich,UK) in HPLC-grade H2O to 
decrease matrix effects by removing urea, electrolytes, and salts, and to enrich polypeptides 
present. Finally, all samples were lyophilized, stored at 4 ºC, and suspended in HPLC-grade 
H2O, shortly before CE-MS analyses, as described (3). CE-MS analyses were performed using a 
P/ACE MDQ capillary electrophoresis system (Beckman Coulter, USA) online coupled to a 
micrOTOF MS (Bruker Daltonic, Germany) as described previously (3, 4). The ESI sprayer 
(Agilent Technologies, USA) was grounded, and the ion spray interface potential was set 
between -4 and -4.5 kV. Data acquisition and MS acquisition methods were automatically 
controlled by the CE via contact close- relays. Spectra were accumulated every 3 s, over a range 
of m/z 350 to 3000.  
Data processing and cluster analysis: Mass spectra were processed using MosaiquesVisu 
software which includes peak picking, deconvolution and deisotoping and has been previously 
described (5,6). 
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Supplementary Table 1 - EFSA health claims approved for olive oil components (7) 
Compound(s) Claim Requirements 
Oleic acid Replacing the saturated fats with 
unsaturated fats in the diet 
contributes to maintaining normal 
levels of blood cholesterol. Oleic 
acid is an unsaturated fat. 
The claim can only be used for foods 
containing at least 45% of unsaturated 
fatty acids 
Phenolic compounds The olive oil polyphenols 
contribute to the protection of blood 
lipids against oxidation reactions 
The claim can be used only for oil 
containing at least 5 mg of 
hydroxytyrosol and its derivatives 
(e.g., tyrosol and oleuropein complex) 
per 20 g of oil. In order to bear the 
claim, the consumer must receive 
information that the beneficial effect is 
obtained with a daily intake of 20 g of 
olive oil 
Vitamin E Vitamin E helps protect cells 
against oxidation reactions 
The claim may be used only for food 
which is at least a source of vitamin E 
(at least 18 mg vitamin E per L/kg) 
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